Company intelligence / Profile preview

Xinghui Tianli

Beijing, Beijing, China

Ownership: Private
Development stage: Other

Overview

Xinghui Tianli (Beijing) Pharmaceutical Technology is a clinical-stage biopharmaceutical company based in Beijing, China, specializing in the discovery and development of innovative small molecule therapeutics. The company primarily focuses on metabolic diseases, such as type 2 diabetes and obesity, as well as oncology. Its lead programs include novel oral GLP-1 receptor agonists and other metabolic regulators designed to provide improved efficacy and patient compliance. Xinghui Tianli leverages its internal R&D capabilities to advance a pipeline of candidates from discovery through early clinical development.

Therapeutic areas: EndocrinologyMetabolic Disorders
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Xinghui Tianli.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xinghui Tianli.

Explore the full profile